Alireza Maleki , Stéphanie Willot , Bertrand Lioger , Victor Guan-Zhide , Mélanie Blin , Anne Hoppe , Cyrille Hoarau
{"title":"杜匹单抗治疗特应性儿童嗜酸性食管炎：一个病例系列","authors":"Alireza Maleki , Stéphanie Willot , Bertrand Lioger , Victor Guan-Zhide , Mélanie Blin , Anne Hoppe , Cyrille Hoarau","doi":"10.1016/j.jahd.2025.100034","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>The holistic management of atopic diseases and allergic diseases has gained significant relevance with the recent discovery of the role of type 2 inflammation, which links these two entities, and the development of new biotherapies targeting this pathway. Eosinophilic esophagitis is a chronic inflammatory condition of the esophagus. Since eosinophilic esophagitis involves type 2 inflammation through IL-4 and IL-13 pathways, dupilumab offers a promising therapeutic option.</div></div><div><h3>Methods</h3><div>In this case series, we reviewed five pediatric atopic patients, aged between 7 and 17 years, with asthma or atopic dermatitis, who received dupilumab for these conditions and were also affected by eosinophilic esophagitis.</div></div><div><h3>Results</h3><div>We found that dupilumab was effective in all atopic manifestation, including achieving complete clinical, eosinophilic esophagitis endoscopic improvements in all patients and complete histological improvement in 60 % of the patients.</div></div><div><h3>Conclusion</h3><div>Our current study confirms a good efficacy of dupilumab, in the holistic management of atopic young pediatric patients with atopic disease including eosinophilic esophagitis.</div></div>","PeriodicalId":100752,"journal":{"name":"Journal of Allergy and Hypersensitivity Diseases","volume":"5 ","pages":"Article 100034"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Dupilumab for atopic children with eosinophilic esophagitis: A case series\",\"authors\":\"Alireza Maleki , Stéphanie Willot , Bertrand Lioger , Victor Guan-Zhide , Mélanie Blin , Anne Hoppe , Cyrille Hoarau\",\"doi\":\"10.1016/j.jahd.2025.100034\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>The holistic management of atopic diseases and allergic diseases has gained significant relevance with the recent discovery of the role of type 2 inflammation, which links these two entities, and the development of new biotherapies targeting this pathway. Eosinophilic esophagitis is a chronic inflammatory condition of the esophagus. Since eosinophilic esophagitis involves type 2 inflammation through IL-4 and IL-13 pathways, dupilumab offers a promising therapeutic option.</div></div><div><h3>Methods</h3><div>In this case series, we reviewed five pediatric atopic patients, aged between 7 and 17 years, with asthma or atopic dermatitis, who received dupilumab for these conditions and were also affected by eosinophilic esophagitis.</div></div><div><h3>Results</h3><div>We found that dupilumab was effective in all atopic manifestation, including achieving complete clinical, eosinophilic esophagitis endoscopic improvements in all patients and complete histological improvement in 60 % of the patients.</div></div><div><h3>Conclusion</h3><div>Our current study confirms a good efficacy of dupilumab, in the holistic management of atopic young pediatric patients with atopic disease including eosinophilic esophagitis.</div></div>\",\"PeriodicalId\":100752,\"journal\":{\"name\":\"Journal of Allergy and Hypersensitivity Diseases\",\"volume\":\"5 \",\"pages\":\"Article 100034\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Allergy and Hypersensitivity Diseases\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2950312425000041\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Allergy and Hypersensitivity Diseases","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2950312425000041","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Dupilumab for atopic children with eosinophilic esophagitis: A case series
Background
The holistic management of atopic diseases and allergic diseases has gained significant relevance with the recent discovery of the role of type 2 inflammation, which links these two entities, and the development of new biotherapies targeting this pathway. Eosinophilic esophagitis is a chronic inflammatory condition of the esophagus. Since eosinophilic esophagitis involves type 2 inflammation through IL-4 and IL-13 pathways, dupilumab offers a promising therapeutic option.
Methods
In this case series, we reviewed five pediatric atopic patients, aged between 7 and 17 years, with asthma or atopic dermatitis, who received dupilumab for these conditions and were also affected by eosinophilic esophagitis.
Results
We found that dupilumab was effective in all atopic manifestation, including achieving complete clinical, eosinophilic esophagitis endoscopic improvements in all patients and complete histological improvement in 60 % of the patients.
Conclusion
Our current study confirms a good efficacy of dupilumab, in the holistic management of atopic young pediatric patients with atopic disease including eosinophilic esophagitis.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
